Reference scaled approach for HVD [RSABE / ABEL]

posted by BE – 2009-03-19 13:30 (6308 d 12:56 ago) – Posting: # 3380
Views: 18,417

Dear HS,

❝ In the EU RSABE is not acceptable anyhow.


Please let me know when you state that RSABE approach is not accepted by EU, are you referring to any guideline. If such is the case, how you do recommend to conduct BE studies for HVD, especially to claim wider limits. I hope you agree that 2 way crossover is not the correct design the depict the innovator variability.

Best Regards,

BE


Edit: Quote restored. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
402 visitors (0 registered, 402 guests [including 23 identified bots]).
Forum time: 03:27 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5